« Factbook Table of Contents

9. Research Grants

• NHLBI Research Grants by Funding Mechanism: Fiscal Year 2007
• NHLBI Research Project Grant, Research Centers Grant, and Other Research Grant Obligations: Fiscal Years 1997–2007
• NHLBI Competing Research Project Grant Applications: Fiscal Years 1997–2007
• NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 1997–2007
• NHLBI Research Project Grants: Amount Funded by Type of Award, Fiscal Years 1997–2007
• NHLBI Research Project Grants: Average Costs, Fiscal Years 1997–2007
• NHLBI Cooperative Agreements (U01 and U10) Programs

NHLBI Research Grants by Funding Mechanism:  Fiscal Year 2007

NHLBI Total Research Grants by Category

Text-only with data points

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations:  Fiscal Years 1997–2007

Text-only with data points are represented in the table below.

^*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 in 2007.
^** Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Research Project Grants,* Research Centers Grants, and Other Research Grant Obligations:  Fiscal Years 1997–2007

Dollars (Thousands)

^*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 in 2007.
^** Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Competing Research Project Grant Applications:*   Fiscal Years 1997–2007

Number Reviewed and Awarded

Text-only with data points are represented in the table below.

Number Reviewed and Awarded and Percent Funded

^*   Includes R01, U01, P01, R03, R15, R21, R29, and R37; R33 beginning in 2001; and DP2 and U19 beginning in 2007.

Percent of Reviewed Applications Funded (Success Rate)

Text-only with data points are represented in the table above.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 1997–2007

Text-only with data points are represented in the table below.

^*   Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research.
^** Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 1997–2007

Dollars (Millions)

^*   Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research.
^** Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Research Project Grants:*  Amount Funded by Type of Award, Fiscal Years 1997–2007

Dollars (Millions)

^*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 beginning in 2007.

Facility and Administrative (F&A) Costs of NHLBI Research Project Grants:* Fiscal Years 1997–2007

Dollars (Thousands)

^*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 beginning in 2007.
^** Excludes Program Evaluation Assessment of $1,216,000.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 1997–2007

Text-only with data points are represented in the table below.

^*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 beginning in 2007.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 1997–2007

Dollars (Thousands)

^*   Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; and DP2 and U19 beginning in 2007.

NHLBI Cooperative Agreements (U01, U10) Programs

Cooperative Agreements were instituted to support discrete, circumscribed projects in areas of an investigator’s spe­cific interest and competency with substantial programmatic participation by the NHLBI during performance of the activity.

Heart and Vascular Diseases Program

AIM HIGH: Niacin Plus Statin To Prevent Vascular Events, Initiated in Fiscal Year 2005

The purpose of this multicenter clinical trial is to determine whether extended-release niacin plus simvastatin is superior to simvastatin alone for preventing or delaying a major CVD event in patients with atherogenic dyslipidemia. Niacin is used to raise HDL (“good”) cholesterol and simvastatin is used to lower LDL (“bad”) cholesterol. Twenty-seven percent of the population will be from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$6,018,096
Fiscal Years 2005–2006— $6,987,287
Total Funding to Date—$13,005,383

Current Active Organizations and Grant Numbers

1. University of Washington
   Seattle, Washington —HL-081616
2. AXIO Research, LLC
   Seattle, Washington —HL-081649

Atherosclerosis, Plaque, and CVD in Communities, Initiated in Fiscal Year 2004

The purpose of this study is to identify correlates of atherosclerotic plaque characteristics and early changes in the vascular wall in a subset of the biethnic Atherosclerosis Risk in Communities (ARIC) cohort. Investigators will use stored DNA samples to test genomic correlates of plaque characteristics and their ability to predict CHD and stroke.

Obligations

Funding History:
Fiscal Year 2007—$2,885,489
Fiscal Years 2004–2006—$13,259,110
Total Funding to Date—$16,144,599

Current Active Organization and Grant Number

1. University of Texas Health Science Center
   Houston, Texas—HL-075572

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D), Initiated in Fiscal Year 2000

The purpose of this trial is to compare alternative treatment strategies for managing patients with type 2 diabetes with angiographically proven coronary artery disease and stable angina or ischemia. Revascularization combined with aggressive medical anti-ischemia treatment will be compared to aggressive medical anti-ischemia treatment alone; simultaneously, researchers will determine whether insulin-sensitizing drugs such as metformin and the glitazones for controlling blood sugar level offer any survival advantage over drugs that increase insulin level. Twenty-one percent of the patients are from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$2,646,947
Fiscal Years 2000–2006—$52,450,028
Total Funding to Date—$55,096,975

Current Active Organizations and Grant Numbers

1. University of Pittsburgh
   Pittsburgh, Pennsylvania—HL-061744
2. St. Louis University
   St. Louis, Missouri —HL-061746
3. Stanford University
   Stanford, California —HL-061748
4. University of Vermont
   Burlington, Vermont —HL-063804

Cardiovascular Cell Therapy Research Network, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

Cardiovascular Heart Study (CHS) Events Follow-Up Study, Initiated in Fiscal Year 2005

The purpose of this project is to continue follow-up of the CHS cohort for cardiovascular events in order to enhance power among subgroups to study associations of CVD risk factors and incidence and prognosis following CVD events in older adults. The additional events will permit greater opportunity to address the study aims by CHS investigators and other researchers interested in making use of the study's extensive database and specimens. Seventeen percent of the participants are from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$1,145,576
Fiscal Years 2005–2006—$2,062,679
Total Funding to Date—$3,208,255

Current Active Organization and Grant Number

1. University of Washington
   Seattle, Washington —HL-080295

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), Initiated in Fiscal Year 2004

The purpose of this trial is to determine whether revascularization of a stenotic renal artery plus medical therapy is associated with improved clinical outcomes compared with medical therapy alone. Twenty-three percent of the participants will be from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$3,306,675
Fiscal Years 2004–2006—$14,837,498
Total Funding to Date—$18,144,173

Current Active Organizations and Grant Numbers

1. University of Toledo Health
   Sciences Campus Toledo, Ohio—HL-071556
2. University of Minnesota, Twin Cities
   Minneapolis, Minnesota—HL-072734
3. University of Virginia
   Charlottesville, Virginia—HL-072735
4. Mid-America Heart Institute of
   St. Luke Hospital Kansas City, Missouri—HL-072736
5. Beth Israel Deaconess Medical Center
   Boston, Massachusetts—HL-072737

Claudication Exercise vs. Edoluminal Revascularization, Initiated in Fiscal Year 2005

The purpose of this study is to test the hypothesis that a strategy of aortoiliac stenting and pharmacotherapy improves maximum walking duration better than a strategy of supervised rehabilitation, exercise, and pharmacotherapy for those with aortoiliac artery obstruction at 6 months. Other objectives are to compare the two treatment groups with a third group, usual care and pharmacotherapy, at 6 months, and to compare maximum walking duration change scores at 18 months, changes in free living daily activity levels, and patient-perceived quality of life among all three groups.

Obligations

Funding History:
Fiscal Year 2007—$1,898,415
Fiscal Years 2005–2006—$2,846,994
Total Funding to Date—$4,745,409

Current Active Organizations and Grant Numbers

1. Rhode Island Hospital
   Providence, Rhode Island —HL-077221
2. Beth Israel Deaconess Medical Center
   Boston, Massachusetts—HL-081656

Clinical Research Consortium To Improve Resuscitation Outcomes, Initiated in Fiscal Year 2004

See Chapter 11. Clinical Trials.

Community-Responsive Intervention To Reduce Cardiovascular Risk in American Indians and Alaska Natives, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Design and Analysis of Genome-Wide Association Studies, Initiated in Fiscal Year 2006

The purpose of this program is to develop and test innovative, informative, and cost-effective study designs and analytical strategies to perform genome-wide association studies on complex diseases. Strategies and tools developed through the program will be made available to the scientific community.

Obligations

Funding History:
Fiscal Year 2007—$1,758,776
Fiscal Year 2006—$1,780,137
Total Funding to Date—$3,538,913

Current Active Organizations and Grant Numbers

1. University of Chicago
   Chicago, Illinois —HL-084689
2. Cornell University Ithaca
   Ithaca, New York —HL-084706
3. University of Chicago
   Chicago, Illinois —HL-084715
4. University of Michigan at Ann Arbor
   Ann Arbor, Michigan—HL-084729
5. University of Maryland, Baltimore
   Baltimore, Maryland—HL-084756
6. Translational Genomics Research Institute
   Phoenix, Arizona—HL-086528

Dynamic Evaluation of Percutaneous Coronary Intervention, Initiated in Fiscal Year 1997

This program, which complements prior NHLBI percutaneous transluminal coronary angioplasty (PTCA) registries and the New Approaches to Coronary Intervention Registry, is evaluating patterns of device usage, as well as immediate and follow-up outcomes in patients undergoing percutaneous transluminal coronary revascularization. Results will provide guidance to the cardiology community in selecting appropriate therapies and in designing clinical trials to evaluate competing devices.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 1997–2006—$6,180,419
Total Funding to Date—$6,180,419

Current Active Organization and Grant Number

1. University of Pittsburgh
   Pittsburgh, Pennsylvania—HL-033292

Family Blood Pressure Program, Initiated in Fiscal Year 1995

The objectives of this program are to identify major genes associated with high blood pressure and to investigate the interactions between genetic and environmental determinants of hypertension in defined populations, many of which consist of specific minority groups. The study consists of collaborative networks that share technology, data, skills, biological materials, and population resources.

Obligations

Funding History:
Fiscal Year 2007—$3,716,949
Fiscal Years 1995–2006—$93,226,792
Total Funding to Date—$96,943,741

Current Active Organizations and Grant Numbers

1. University of Utah
   Salt Lake City, Utah —HL-054471
2. Washington University
   St. Louis, Missouri —HL-054473
3. University of Texas
   Health Science Center
   Houston, Texas—HL-054481
4. Pacific Health Research Institute
   Honolulu, Hawaii—HL-054498
5. University of Michigan at Ann Arbor
   Ann Arbor, Michigan—HL-054512

Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN), Initiated in Fiscal Year 2000

The purpose of this study is to document CVD and CVD risk factors in approximately 40 extended families (1,214 members from villages in Northern Alaska). Scientists seek to identify and characterize genes that contribute to CVD in this unique and understudied population.

Obligations

Funding History:
Fiscal Year 2007—$2,029,384
Fiscal Years 2000–2006—$11,838,340
Total Funding to Date—$13,867,724

Current Active Organizations and Grant Numbers

1. MedStar Research Institute
   Hyattsville, Maryland—HL-064244
2. Norton Sound Health Corporation
   Nome, Alaska —HL-082458
3. Southwest Foundation for Biomedical Research
   San Antonio, Texas—HL-082490

Girls Health Enrichment Multisite Studies (GEMS), Initiated in Fiscal Year 1999

The objective of this project is to develop and test interventions to prevent obesity by decreasing weight gain during the high-risk transitional period from pre-puberty to puberty in black girls who are at risk for developing obesity. Phase I (developmental and pilot studies) was completed in FY 2002. Two sites began Phase II trials in FY 2003.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 1999–2006—$19,418,195
Total Funding to Date—$19,418,195

Current Active Organizations and Grant Numbers

1. St. Jude Children's Research Hospital
   Memphis, Tennessee—HL-062662
2. Stanford University
   Stanford, California —HL-062663

Heart Failure: A Controlled Trial Investigating Outcomes of Exercise (HF-ACTION), Initiated in Fiscal Year 2002

The purpose of this trial is to determine the long-term safety and effectiveness of exercise training for patients with heart failure. Patients receiving the exercise regimen also will receive standard care and will be compared with patients receiving standard care alone. Thirty-eight percent of the participants are from minority populations.

Obligations

Funding History:
Fiscal Year 2007—$2,846,477
Fiscal Years 2002–2006—$34,118,122
Total Funding to Date—$36,964,599

Current Active Organizations and Grant Numbers

1. Duke University
   Durham, North Carolina —HL-063747
2. Case Western Reserve University
   Henry Ford Health System
   Detroit, Michigan—HL-064250
3. Oregon Health & Science University
   Portland, Oregon—HL-064257
4. Washington University
   St. Louis, Missouri —HL-064264
5. University of Colorado
   Health Sciences Center
   Denver, Colorado—HL-064265
6. Duke University
   Durham, North Carolina —HL-066461
7. Emory University
   Atlanta, Georgia —HL-066482
8. Wake Forest University
   Winston-Salem, North Carolina—HL-066491
9. Ohio State University
   Columbus, Ohio —HL-066494
10. University of Alabama at Birmingham
    Birmingham, Alabama—HL-066497
11. Case Western Reserve University
    Philadelphia, Pennsylvania—HL-066501
12. Boston Medical Center
    Boston, Massachusetts —HL-068973
13. University of California, Los Angeles
    Los Angeles, California—HL-068980

Heart Failure Clinical Research Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Home Automatic External Defibrillator Trial (HAT), Initiated in Fiscal Year 2002

The purpose of this trial is to compare standard response (call 9–1–1 and give cardiopulmonary resuscitation) to sudden cardiac arrest to standard response augmented with automatic external defibrillator use provided by a spouse or other family member in 7,000 survivors of an anterior wall MI. The primary end point is mortality.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 2002–2006—$17,178,972
Total Funding to Date—$17,178,972

Current Active Organization and Grant Number

1. Seattle Institute for Cardiac Research
   Seattle, Washington—HL-067972

IMMEDIATE Trial: Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care, Initiated in Fiscal Year 2004

The purpose of this program is to study the effects of early administration of glucose, insulin, and potassium (GIK) in reducing mortality in patients from acute coronary syndrome (ACS). Patients experiencing an ACS (including AMI and unstable angina pectoris) will be treated with GIK as soon as possible in prehospital emergency medical service settings or immediately upon arrival for those presenting to emergency departments.

Obligations

Funding History:
Fiscal Year 2007—$0
Fiscal Years 2004–2006—$25,650,639
Total Funding to Date—$25,650,639

Current Active Organizations and Grant Numbers

1. New England Medical Center Hospitals
   Boston, Massachusetts—HL-077821
2. State University of New York
   Stony Brook, New York—HL-077822
3. New England Medical Center Hospitals
   Boston, Massachusetts—HL-077823
4. New England Medical Center Hospitals
   Boston, Massachusetts—HL-077826

Improved Measures of Diet and Physical Activity for the Genes and Environment, Initiated in Fiscal Year 2007

The purpose of this program is to support the development of technology to make precise, quantitative measurements of personal exposure to environmental chemical or biological agents, diet, physical activity, and psychosocial stress.

Obligations

Funding History:
Fiscal Year 2007—$2,632,681
Total Funding to Date—$2,632,681

Current Active Organizations and Grant Numbers

1. University of Pittsburgh
   Pittsburgh, Pennsylvania—HL-091736
2. Massachusetts Institute of Technology
   Cambridge, Massachusetts—HL-091737
3. Princeton Multimedia Technologies Corporation
   Princeton, New Jersey—HL-091738

Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

NHLBI Clinical Proteomics Program, Initiated in Fiscal Year 2005

The purpose of this program is to promote systematic, comprehensive, large-scale validation of existing and new candidate protein markers that are appropriate for routine use in the diagnosis and management of heart, lung, and blood diseases and sleep disorders. The Program will facilitate validation of protein panels that may be used to predict disease susceptibility or to assist in differential diagnosis, disease staging, selection of individualized therapies, or monitoring of treatment responses. It will also establish a high-quality education and skills development program to ensure that scientists develop the expertise needed to address the complex, multifaceted challenges in clinical proteomics.

Obligations

Funding History:
Fiscal Year 2007—$4,920,952
Fiscal Years 2005–2006—$10,024,329
Total Funding to Date—$14,945,281

Current Active Organizations and Grant Numbers

1. Mayo Clinic College of Medicine
   Rochester, Minnesota—HL-081331
2. Vanderbilt University
   Nashville, Tennessee —HL-081332
3. University of Colorado
   Denver, Colorado —HL-081335
4. Massachusetts General Hospital
   Boston, Massachusetts—HL-081341

Occluded Artery Trial (OAT), Initiated in Fiscal Year 1999

The purpose of this study is to determine whether percutaneous revascularization to open an occluded artery within a few days or as long as a month following an acute MI in asymptomatic patients improves their outcome. Although the benefits of early restoration of blood flow following an acute MI have been well-established, it is not known whether later intervention is also beneficial. The trial is in its follow-up phase.

Funding History:
Fiscal Year 2007—$1,452,378
Fiscal Years 1999–2006—$17,224,514
Total Funding to Date—$18,676,892

Current Active Organizations and Grant Numbers

1. New York University
   School of Medicine
   New York, New York—HL-062509
2. Maryland Medical Research
   Institute, Inc.
   Baltimore, Maryland—HL-062511

Partnership Programs To Reduce Cardiovascular Health Disparities, Initiated in Fiscal Year 2004

The objectives of this study are to improve the provider and patient approaches to treatment of hypertension and diabetes, modify physician-related barriers to minority enrollment in clinical trials, improve patient adherence to treatment plans, and build sustainable research programs at minority-serving institutions.

Obligations

Funding History:
Fiscal Year 2007—$7,330,477
Fiscal Years 2004–2006—$20,929,126
Total Funding to Date—$28,259,603

Current Active Organizations and Grant Numbers

1. Bon Secours Hospital Baltimore, Inc.
   Baltimore, Maryland—HL-079150
2. University of Maryland
   Baltimore Professional School
   Baltimore, Maryland—HL-079151
3. Queen's Medical Center
   Honolulu, Hawaii —HL-079152
4. Cooper Green Hospital
   Birmingham, Alabama —HL-079153
5. Emory University
   Atlanta, Georgia —HL-079156
6. Denver Health and Hospital Authority
   Denver, Colorado—HL-079160
7. University of Hawaii at Manoa
   Honolulu, Hawaii —HL-079163
8. University of Alabama at Birmingham
   Birmingham, Alabama—HL-079171
9. University of Colorado
   Health Sciences Center
   Denver, Colorado—HL-079208
10. Morehouse School of Medicine
    Atlanta, Georgia